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The evolution of drug resistance 
mechanisms in pathogenic 
microorganisms poses a global health crisis, 
and millions of people are at risk if the 
problem is not addressed in the laboratory 
and translated to the clinic. What role do 
diagnostics have in managing the challenge 
of antimicrobial resistance?
%CTG[#PP&|$WTPJCOAntibiotic 
resistance has emerged as a global health 
crisis and if we cannot reverse the trend we 
are on a course towards a post-antibiotic era. 
There are several ways that diagnostic testing 
can assist in managing this challenge.
At a very high level, rapid near-patient 
diagnostic assays to distinguish viral 
from bacterial infections may prevent 
treatment with unnecessary antibiotics. 
If a bacterial infection is present, defining 
the aetiology and antibiotic susceptibility 
profile is essential to optimize and narrow 
antimicrobial therapy as quickly as possible. 
Whereas traditional methods used in clinical 
microbiology laboratories would typically 
require 48 h (or longer) for definitive results, 
rapid diagnostic methods are becoming 
available for routine clinical use; some of 
these methods can provide results within 
hours. Although rapid tests for infection 
of antimicrobial resistance, as it limits the 
exposure of patients and environments to 
antibacterials under only those circumstances 
in which the drugs are likely to improve the 
health status of an individual. The more 
inappropriately antibacterials are used, the 
more we risk the erosion of the utility of a 
drug due to resistance. With the immense 
amount of time and resources that it takes to 
discover new safe and effective antibiotics, 
diagnostics help the medical community to 
preserve the utility of these precious drugs.
2CVTKEG0QTFOCPP Diagnostic techniques 
may contribute to the identification of 
rapidly emerging resistance traits. First, 
such a rapid identification can contribute 
to better antibiotic stewardship. Rapid 
adaptation of the antibiotic therapy to 
the resistance phenotype of the infecting 
organism may save the lives of patients, as 
it has been shown that the optimization 
of the antibiotic therapy during the first 
6–12 h of infection is crucial for the treatment 
of life-threatening  infections. This is 
particularly true for infections caused by 
Gram-negative bacteria, such as those species 
that are currently the main focus of antibiotic 
resistance research. For example, species 
in the Enterobacteriaceae family that may 
produce extended-spectrum β-lactamases 
that confer resistance to extended-spectrum 
cephalosporins, carbapenemases that confer 
resistance to carbapenems (imipenem, 
meropenem or ertapenem), or that are 
resistant to polymyxins. Second, the rapid 
identification of resistance traits may 
contribute to the identification of patients 
who are infected with resistant pathogens 
but do not show symptoms, particularly in 
hospital settings. In turn, the immediate 
isolation of an infected individual in 
healthcare facilities could prevent the 
development of outbreaks that are associated 
with multidrug-resistant bacteria and 
save costs.
,WUVKP1o)TCF[ Rapid and comprehensive 
diagnostics are key for managing 
antimicrobial resistance; they enable the 
improved management of patients who are 
infected, improved antimicrobial stewardship 
and the development of new antimicrobials. 
The first clinical question is whether the 
can have a positive effect at the individual 
patient level, diagnostics have a broader 
role in managing antimicrobial resistance. 
Rapid susceptibility testing is essential to 
support clinical trials for new anti-infective 
agents, and aggregate contemporary 
data on local and regional antimicrobial 
resistance trends can facilitate antimicrobial 
stewardship, epidemiological surveillance and 
epidemiological efforts.
,GPPKHGT.GGFU From my perspective as 
a leader of an antibacterial drug discovery 
group in the pharmaceutical industry, 
diagnostics enable the appropriate use of new 
drugs when they are introduced into clinical 
practice and throughout their commercial 
lifespan. It is important for medical staff and 
treating physicians to understand which 
drugs will benefit an individual patient, and it 
is important for the antimicrobial stewardship 
committees to understand how to address 
overall patient needs at their institutions 
with respect to antimicrobial resistance. 
Without a diagnostic device that indicates 
whether a patient is likely to benefit from a 
specific drug, the drug could be misused or 
not used at all, even if it was available and 
able to save the lives of patients. Appropriate 
use is a cornerstone in the management 
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Abstract | Antimicrobial resistance constitutes a global burden and is one of 
the major threats to public health. Although the emergence of resistant 
microorganisms is a natural phenomenon, the overuse or inappropriate use of 
antimicrobials has had a great effect on resistance evolution. Rapid diagnostic 
tests that identify drug-resistant bacteria, determine antimicrobial susceptibility 
and distinguish viral from bacterial infections can guide effective treatment 
strategies. Moreover, rapid diagnostic tests could facilitate epidemiological 
surveillance, as emerging resistant infectious agents and transmission can be 
monitored. In this Viewpoint article, several experts in the field discuss the 
drawbacks of current diagnostic methods that are used to identify antimicrobial 
resistance, novel diagnostic strategies and how such rapid tests can inform drug 
development and the surveillance of resistance evolution.
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patient needs antimicrobial therapy, and, 
second, if a microbial infection is present, 
what antimicrobial is appropriate for 
successful treatment. Any delay in appropriate 
antimicrobial therapy can lead to increased 
mortality in the case of certain infections; for 
example, ventilator-associated pneumonia 
and sepsis1. The rapid identification of 
pathogens and antimicrobial resistance or 
susceptibility will change the way clinicians 
manage infection, reducing the duration of 
to be available before the administration 
of empirical treatment, particularly when 
dealing with life-threatening infections. 
Providing a comprehensive microbiological 
diagnosis before the second dose of empirical 
treatment may be sufficient to improve 
patient outcomes and stewardship until 
more rapid diagnostic technologies are 
available. Moreover, rapid and comprehensive 
diagnostics will enable the development 
and use of narrow-spectrum antimicrobials 
by providing pathogen and resistance 
information in hours rather than days, 
and enabling early targeted therapy.
Jean Patel. Antimicrobial use is a 
primary driver of resistance. The CDC 
estimates that the use of 50% of antibiotics 
(antimicrobials used to treat bacterial 
infections) administered in hospitals 
is inappropriate or unnecessary. New 
diagnostics could fundamentally change 
when and how antibiotics are used. 
A diagnostic test that could accurately 
differentiate a bacterial infection from a 
viral infection or non-infectious condition 
would eliminate most of the unnecessary 
use of antibiotics. A test that could rapidly 
determine whether a bacterial infection 
was likely to respond to a specific antibiotic 
(that is, if it is susceptible) would mean that 
doctors could pick an appropriate drug 
faster, thereby improving patient outcomes, 
decreasing the risk of adverse drug events 
and reducing the potential for pathogen 
spread. Another crucial role for diagnostics 
is identifying patients who are colonized, but 
may not be infected, with resistant bacteria. 
These test results can identify hidden 
reservoirs for transmission, especially in 
healthcare settings.
What are the drawbacks of the methods 
currently used to identify antimicrobial 
resistance?
%#&$ Most of the commercially 
available rapid methods for identifying 
antimicrobial resistance are genotypic 
methods — that is, methods that rely on 
the detection of resistance genes or gene 
products. There are several limitations to 
these approaches. The first is that genotypic 
methods can be effective at predicting 
antimicrobial resistance, but they do not 
inform antimicrobial susceptibility. In 
addition, with these approaches ‘you only get 
what you look for’ (typically a small panel 
of resistance determinants is evaluated). 
Furthermore, not all resistance phenotypes 
are conferred by a straightforward genotype, 
empirical therapy and facilitating the early 
initiation of targeted narrow-spectrum 
treatment with proven antibiotic activity 
against the causative agent of infection. The 
ultimate goal for rapid diagnostics should 
be the identification of the pathogen and 
antimicrobial susceptibility directly from 
clinical samples at point of care within 
approximately 30 min. However, currently, 
the fastest diagnostic testing methods 
still take hours, and results are unlikely 
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and genotypic methods would not detect 
emerging resistance patterns for which the 
genotype has not been defined.
Phenotypic methods have the advantage 
of predicting both resistance and susceptibly 
in a relatively unbiased way. However, 
microbial growth-based methods have 
the major disadvantages of requiring a 
relatively large number of viable organisms 
for analysis and of the methods being slow. 
In addition, these growth-based methods 
are best suited for central laboratory testing 
and not near-patient testing. Furthermore, 
although phenotypic methods used 
in clinical laboratories today produce 
reproducible results2,3, these in vitro assays 
cannot approximate the complex ecology of 
infection and do not account for other factors 
that can influence the outcome of infection, 
such as host response, biofilm formation, 
interactions with other microorganisms and 
bioavailability in tissue.
A logistical challenge is that when new 
anti-infective agents are cleared for use, there 
may be a great lag (sometimes years) before 
methods to measure in vitro susceptibility 
are developed and/or before these laboratory 
reagents have regulatory clearance for 
routine diagnostic use. A lack of methods 
for routine susceptibility testing may limit 
the clinical use of these new agents.
Last, there are some important gaps 
in diagnostic methods; for example, we 
have very limited tools for the diagnosis 
of fungal and mycobacterial infections, 
and even fewer for the rapid detection of 
antimicrobial resistance in these pathogens. 
Another example is drug-resistant Neisseria 
gonorrhoeae infections, which are an 
urgent public health threat. Although rapid 
molecular assays exist that provide sensitive 
and specific detection of this pathogen 
in clinical specimens, the detection of 
antimicrobial resistance genes is not a 
component of these assays. A potential 
downside to these rapid molecular 
methods is an absence of culture isolates for 
susceptibly testing, which could be important 
both for the care of an individual patient 
but also for gathering population-level 
surveillance data.
J.L. For many infection types, the turnaround 
time for diagnosis and the implementation 
of diagnostic information is rather slow, 
so changes from empirical to targeted 
treatment, or inappropriate to appropriate 
therapy, may not occur on an effective 
timescale. This could limit the benefit 
of niche or narrow-spectrum agents, 
which are a growing emphasis within the 
resistance has changed this situation, 
highlighting the need for rapid diagnostics. 
Increasing antimicrobial resistance is also 
forcing changes in recommended first-line 
treatments, replacing drugs to which 
pathogens have developed resistance with 
drugs that pathogens are susceptible to but 
are often less effective or cause unwanted 
adverse effects. An example includes the 
recent change from using trimethoprim to 
using nitrofurantoin for the treatment of 
uncomplicated urinary tract infections in 
the United Kingdom; nitrofurantoin must 
be avoided in patients with reduced kidney 
function owing to poor activity (reduced 
renal elimination of nitrofurantoin, leading 
to a decreased concentration in the urinary 
tract) and toxic adverse effects (increased 
concentration of the drug in the blood). 
Another example is the switch from using 
ciprofloxacin to cephalosporins for the 
treatment of gonorrhoea, as cephalosporins 
are less effective for the treatment of 
pharyngeal infection. Trimethoprim or 
ciprofloxacin could still be used in the 
approximately 60% of infections caused 
by susceptible pathogens5,6, if these could 
be identified in a timely fashion using 
rapid diagnostics. PCR tests, particularly 
more recent sample-to-answer multiplex 
PCR technologies (for example, Biofire 
Filmarray and Curetis Unyvero panels), are 
becoming more commonly used in clinical 
microbiology. However, the resistance 
markers on these panels are not sufficiently 
comprehensive to provide clinically 
actionable results in most cases and their 
future use is questionable, as they are used in 
parallel to culture-based methods but cannot 
replace them.
J.P. Current testing methods for selecting 
an effective antibiotic can be too slow or 
provide limited information. Specifically, 
traditional phenotypic susceptibility 
testing results are usually available 36–72 h 
after the sample is collected from the 
patient. This is too slow to help with 
initial treatment decisions and, because 
of the delay, results are often not used to 
de-escalate or update the treatment plan 
when such action is warranted. Molecular 
tests, such as PCR or hybridization tests for 
resistance mechanisms, are much faster, with 
turnaround times of 1–4 h. These tests can 
be very useful for treatment decisions for 
infections caused by Gram-positive bacteria, 
such as Staphylococcus aureus, because the 
number of resistance mechanisms in this 
species is limited. By contrast, resistant 
Gram-negative bacteria, such as species in 
antibacterial discovery and development 
arena, in clinical practice. In addition, it 
is not straightforward to add new drugs 
to existing testing device platforms, so the 
availability of all approved test formats for a 
particular drug typically does not coincide 
with the introduction of a new drug onto 
the market. This potentially limits the use 
of the new drug, even when otherwise 
appropriate. Finally, the current FDA 
guidelines for antimicrobial susceptibility 
testing devices licensed for use in the United 
States do not allow the use of these devices 
to provide susceptibility data for organisms 
that are not part of the approved indication 
for a new drug4, so the use of a drug to treat 
pathogens that are otherwise sensitive to an 
antibiotic is hampered by the lack of available 
susceptibility testing for those pathogens that 
might be treatable with a particular drug on 
the basis of preclinical and non-clinical data.
P.N. The techniques that are currently used 
for the identification of antibiotic resistance 
(broth dilution and disk diffusion techniques) 
are sometimes time-consuming, expensive 
and not broad enough. Many diagnostic 
techniques used for antibiotic susceptibility 
testing still require culturing of the infective 
agent, which can take at least 6–18 h. Such 
culture-dependent methods can thus delay 
the choice of an appropriate antimicrobial 
therapy; that is, the choice of the antibiotic 
to which the bacteria is susceptible. Many 
molecular techniques are already available 
for the detection of several resistance traits. 
However, their main drawbacks are that they 
are still expensive, they only detect known 
genes, they cannot be used directly for many 
clinical samples that contain too few bacterial 
isolates (for example, for blood samples), 
and the presence of a resistance gene does 
not necessarily correlate with the resistance 
phenotype. In fact, gene expression level and 
combined mechanisms of resistance may 
make those resistance traits difficult to predict 
through the use of molecular techniques 
alone. Indeed, several and different combined 
biochemical mechanisms may provide the 
same resistance phenotype.
,1o) In light of rapidly increasing 
antimicrobial resistance, current 
culture-based methods are no longer fit 
for purpose for the diagnosis of infection, 
particularly acute infection, owing to the slow 
turnaround time of results. Until relatively 
recently, empirical broad-spectrum treatment 
worked for the vast majority of infections, and 
culture results were only used clinically when 
treatment failed. Increasing antimicrobial 
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the Enterobacteriaceae, Acinetobacter spp. 
and Pseudomonas spp., have many different 
resistance determinants (resistance genes 
and mutations), and often the phenotypic 
resistance results from a combination 
of determinants that encode resistance 
mechanisms acting together at different 
sites in the bacterial cell. As resistance is 
so complex, tests that detect only a subset 
of resistance mechanisms provide limited 
information for picking a therapeutic agent.
What novel diagnostic strategies and 
approaches can be implemented to 
identify antimicrobial drug resistance? What 
parameters need to be considered when 
developing phenotypic and genotypic tests 
for the rapid and accurate detection (or 
confirmation) of antimicrobial resistance and 
when selecting useful therapeutic agents?
%#&$ There are several novel strategies 
that can be implemented. It is well established 
that outpatient visits for respiratory infections 
are the setting in which the most unnecessary 
antimicrobials are prescribed. Near-patient 
testing to rule out bacterial infection or 
confirm viral aetiology may be a simple 
approach to reducing the unnecessary use 
of antimicrobials.
In the setting of serious bacterial infection, 
rapid phenotypic methods are needed. The 
ideal method would provide definitive results 
directly from the clinical specimen within 
5–8 h of specimen collection; with these 
performance characteristics, the second 
dose of antibiotics administered could be 
directed therapy.
Although phenotypic methods to 
detect both resistance and susceptibility 
to antibiotics are desired, conventional 
growth-based systems are slow, and 
attempts to increase the doubling time of 
microorganisms have resulted in very limited 
success. Thus, there is a need to focus on the 
development of new methods to detect this 
growth with improved sensitivity, an example 
of which could be measuring metabolic end 
products as a surrogate for microbial growth. 
In addition, methods that measure the host 
response to therapy are desired. For many 
infections, the optimal duration of antibiotic 
treatment is not known, but measuring the 
host response could be an effective tool 
to establish an appropriate end point to 
antimicrobial therapy.
Thus, factors that should be considered 
when developing new assays include sample 
requirements (that is, can testing be carried 
out directly on a clinical specimen or on a 
pure culture of organism), analysis time, the 
P.N. The novel strategies for detecting 
emerging resistance traits may be based on 
molecular biology techniques, immunology, 
biochemistry and rapid culture techniques. 
Novel molecular techniques will involve 
novel machines based mostly on a PCR 
technique. However, the costs associated with 
purchasing and maintaining such devices 
are currently still too high for them to be 
available to many institutions and hospitals. 
Following the development and approval, 
such novel technologies can be used as a 
point-of-care technology in hospital settings, 
such as intensive care units, as well as for 
general healthcare providers in medical 
practices. The spread of techniques such as 
the whole-genome sequencing may provide 
some help for the rapid identification 
of specific resistance traits. However, 
whole-genome sequencing takes at least 
several hours to obtain results. Currently, 
this technique is widely used to compare 
susceptible strains that could be a potential 
source of outbreaks.
Immunological techniques that are based 
on antibody–antigen reactions are also 
being developed, as they provide simple, 
cost effective and convenient solutions 
for the identification of several antibiotic 
resistance traits. Moreover, rapid culture 
methods, such as those for identifying 
resistance to polymyxins in members of the 
Enterobacteriaceae (rapid polymyxin NP 
test), as well as biochemical approaches, such 
as those used to identify broad-spectrum 
enzymes (such as extended-spectrum 
β-lactamases or carbapenemases, using the 
rapid ESBL NP test and rapid Carba NP 
test, respectively), already enable the rapid 
identification of resistance markers, although 
the underlying molecular mechanisms 
of resistance remain unknown. These 
techniques provide results within 2 h.
Overall, the parameters of any novel 
diagnostic technique to be studied are 
sensibility, specificity, and positive and 
negative predictive values. In addition, 
a particular concern is that rapid tests should 
take into account that there is not necessarily 
a correlation between the resistance 
phenotype and genotype.
,1o) Recently, agnostic metagenomic 
sequencing has been tested for the 
rapid and comprehensive diagnosis of 
pathogens and antimicrobial resistance, 
with a first trial currently ongoing for 
hospital-acquired pneumonia. Rapid 
nanopore metagenomic sequencing can 
identify a pathogen (bacteria, viruses, fungi 
and parasites) and its associated resistance 
breadth of the panel of microorganisms and 
antimicrobial agents that can be detected, 
and the flexibility of the system to expand 
testing to additional microorganisms and 
antimicrobial agents as required.
J.L. There are some new rapid image-based 
technologies that could provide the 
turnaround of information more quickly 
in a clinical setting. Current culture-based 
methods that require isolated colonies 
to grow before susceptibility data can 
be acquired can take up to 48 h or more, 
depending on the time lag from patient 
sampling to the start of the clinical 
microbiology laboratory processes, the 
testing time and the time to turn data around 
and have it reviewed by a physician. New 
methods that can use direct-from-sample 
testing and that can report drug susceptibility 
without the need for standard culture 
techniques may shorten that time window by 
at least one day, perhaps more. For example, 
on the basis of the information disclosed on 
their website, the Accelerate PhenoTest BC kit 
can identify species from blood culture in less 
than 90 min and antibiotic susceptibility in 
less than 7 h7. There are also some hand-held 
nucleic acid-based rapid diagnostic devices 
being developed that may be useful in field 
settings, especially when the practicality of 
culture-based diagnostics is not feasible but 
the likelihood of certain pathogens is high8. 
What parameters need to be considered 
when developing phenotypic and genotypic 
tests for the rapid and accurate detection (or 
confirmation) of antimicrobial resistance and 
when selecting useful therapeutic agents? To 
me, as a drug discoverer, the most important 
aspect of new diagnostic tools is that they 
provide clarity about when it is appropriate 
to use a particular agent. However, knowing 
that an organism contains genes that could 
confer resistance to a particular drug still 
does not necessarily inform what that 
organism is susceptible to. Thus, a treating 
physician really benefits when they are 
given a list of agents that will work against a 
particular pathogen, not just what will not 
work. To achieve this, a device will need to 
robustly report susceptibility data, not just 
the presence of a resistance determinant, 
to a panel of available drugs. In addition, 
the presence of genetic material does not 
always correlate with the expression levels 
of those genes, nor does it necessarily take 
into account other intrinsic or acquired 
mechanisms that contribute to the loss of 
susceptibility; therefore, a phenotypic test 
method will often need to be paired with a 
genotypic method to capture that complexity.
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profile within hours (for example, 4 h for 
the diagnosis of urinary tract infections9) 
in a single test. This is a very powerful 
technique that is likely to have a big effect on 
clinical microbiology in the coming years. 
However, the detection of antimicrobial 
resistance (rather than susceptibility) is not 
ideal, as it informs clinicians on what not 
to prescribe rather than providing clear 
treatment options. Also, genotypic resistance 
may not always correlate with phenotypic 
resistance (for example, resistance related to 
gene expression levels), and many resistance 
mechanisms are multifactorial and not 
yet fully understood. Rapid susceptibility 
testing directly from clinical samples is 
challenging, but should be the ultimate goal 
for diagnostic technologies attempting to 
replace culture-based methods.
MALDI-TOF and rapid microscopy- 
based susceptibility testing methods are 
available (for example, Accelerate PhenoTest 
BC), but these systems currently rely on 
cultured clinical samples and/or isolates, 
which are typically only available 24 h post-
incubation. Although combining quantitative 
PCR (qPCR)-based detection (or, in the 
future, rapid metagenomics) of pathogen 
nucleic acid and shortened culture of isolates 
in media containing antibiotics has been 
shown to be an effective method for testing 
antimicrobial susceptibility, the requirement 
for isolated bacteria increases the turnaround 
time for results. It remains to be seen whether 
such technologies can be optimized to work 
directly on clinical samples, particularly 
those that contain high bacterial loads, 
such as samples from patients with urinary 
tract infections.
J.P. Genotypic testing is fast and 
reproducible, and whole-genome 
sequencing is becoming more affordable. 
Sequencing data can more accurately detect 
antibiotic resistance because databases that 
correlate molecular findings to phenotypic 
resistance, such as ResFinder, are more 
robust. Sequencing has the additional 
benefits of providing molecular typing 
data to help with outbreak detection 
and helping infection control experts to 
better understand transmission dynamics. 
Advances in metagenomic techniques 
hold promise that we will soon be able to 
obtain crucial antimicrobial resistance data 
from slow-growing pathogens, fastidious 
pathogens or pathogens that are now 
commonly detected by culture-independent 
diagnostics, which, although rapid, 
provide less data-rich results. For these 
and other reasons, sequencing approaches, 
Aside from antibiotics, novel therapeutic 
approaches are necessary. Academics and 
industry must work together to improve 
our understanding of the microbial 
disruption that occurs when antimicrobial 
therapy is administered and what can 
be done to combat this. Furthermore, 
an improved understanding of how our 
resident microbiota contributes to health 
and disease, and what microorganisms are 
most important to resistant colonization or 
infection with pathogens, is an important area 
of investigation.
J.L. It is an exciting time in antibacterial 
drug discovery and diagnostic innovation. 
I attended the American Society for 
Microbiology (ASM) Microbe meeting 
2017 and there was a session called “Bad 
Bugs, New Drugs — but No Tests!”. The 
room was packed as a panel consisting 
of a drug developer, a hospital-based 
clinical microbiologist, a diagnostic device 
manufacturer, and an infection control 
specialist and Jean Patel (an epidemiology 
expert from the CDC), helped the 
microbiology community to understand 
the latest developments in the diagnostic 
device arena. In my opinion, every academic 
and industry scientist who is innovating 
diagnostic approaches should attend events 
such as this one so that they can become 
aware of the needs and limitations of all 
aspects of the field. This also gives them a 
few points of contact with whom to interact 
and begin to learn more about the practical 
nature of diagnostics and where innovation 
can truly have an effect. Working across 
drug development and device development 
as a coordinated and collaborative effort 
is crucial, both from a regulatory and 
from a practical standpoint. Open lines of 
communication among clinical laboratory 
staff, healthcare providers, drug developers 
and device innovators is crucial to appreciate 
the goals and the needs of each partner, so 
that innovators can deliver products that meet 
and exceed the expectations of the individual 
stakeholders, and the decision makers who 
back them, by providing necessary resources. 
Spending time ‘walking in each other’s shoes’ 
can teach you a lot about what excites each 
party and what barriers may lie in the way 
of a great idea being adopted into clinical 
practice. Finally, we need to really support 
training and careers in clinical microbiology. 
Without trained staff who can implement 
the use of new devices and provide accurate 
information back to physicians and other 
healthcare personnel, the true societal value 
of new devices is at risk.
including metagenomics, will initially be 
most important for pathogens such as 
Mycobacterium tuberculosis, N. gonorrhoeae 
and Salmonella spp.
Sequencing will be a powerful tool for 
the rapid identification of antimicrobial 
resistance, but phenotypic antimicrobial 
susceptibility testing is likely to remain the 
‘gold standard’ testing strategy for selecting a 
therapeutic agent. This is because genotypic 
testing can only tell us about resistance 
mechanisms and determinants that have 
already been discovered, which means 
that new resistance could be missed and 
spread undetected. Although phenotypic 
susceptibility methods have slow turnaround 
times, technological advances are shortening 
these delays. Recent phenotypic innovations 
include single-cell light microscopy, mass 
spectrometry and measuring genomic 
transcription after antibiotic exposure. These 
methodological strategies are all faster than 
waiting for bacteria to grow overnight in the 
presence of antibiotics. These methods can 
become even faster if coupled with advances 
in technologies that capture and test low 
numbers of infectious agent from clinical 
specimens. This would eliminate or shorten 
the incubation time required to have enough 
bacteria for testing using current methods. 
The FDA recently approved a phenotypic 
susceptibility method that can produce 
results within about 6.5 h of a positive blood 
culture10. This is a great advancement and 
hopefully even faster phenotypic methods 
will be available in the future.
What opportunities are there for 
academics, clinicians and scientists in 
industry to work together to innovate and 
implement diagnostics that improve patient 
care and public health?
%#&$ Translational research — an 
ongoing process of iteration — is essential 
to drive the innovation that is needed to 
improve patient outcomes and public health. 
For the success of this translation, academics 
and clinicians will need to work with 
industry partners to develop and evaluate 
new products and move them forward 
towards market, and diagnostic methods 
need to be developed in conjunction with 
new antimicrobial agents. Equally important 
is the need for ongoing surveillance to 
identify emerging mechanisms of resistance 
as early as possible and the characterization 
of resistance mechanisms; this knowledge 
is essential for the ongoing development of 
diagnostic methods and antimicrobial agents 
for emerging resistance mechanisms.
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P.N. Academics who are working in 
association with hospitals have a privileged 
situation to detect emerging resistance 
phenomena, as they have access to samples 
and patients who are infected. On the basis 
of their observations, they may be in a 
position to develop specific novel diagnostic 
tests that correspond to a clinical need, 
such as the detection of new drug-resistant 
pathogens. However, the development of 
resistance tests mostly relies on industry, as 
the microbiological diagnostic industry has 
extensive know-how and the money to invest 
rapidly in the field. As extensively done in the 
past, clinicians and clinical microbiologists 
will have a key role in the evaluation and 
implementation of any novel diagnostic tests 
that are being developed by industry, and 
they will have the main role in choosing 
and retaining the most suitable technique 
to identify a resistance trait as a source of 
infection or at the carrier state, based on the 
clinical value of each test and their cost.
,1o) Innovation, translation and 
implementation skills are all required 
for new diagnostic tests to reach the 
bedside; hence, diagnostics innovators in 
different areas naturally collaborate closely. 
Recently, governments have provided more 
funding for research and development 
into antimicrobial resistance and this has 
opened many additional opportunities for 
academic, industrial and clinical innovators 
to work together. The quality and scope 
of diagnostic clinical trials have improved 
with investment, with recent studies 
considering more than test specificity and 
sensitivity, and turnaround time, addressing 
antimicrobial stewardship, cost–benefit 
analysis and scientist and clinician behaviour 
in relation to new diagnostics (for example, 
the INHALE hospital-acquired pneumonia 
diagnostic trial). These multidisciplinary 
approaches are crucial if better diagnostics 
are to be developed and implemented in 
clinical microbiology. An example of a 
potential area for future multidisciplinary 
collaboration is combining the detection 
of human biomarkers of infection, such as 
blood transcriptional biomarkers11, with 
the detection of the pathogen and the 
antimicrobial resistance profile in a single 
test. For example, using host and pathogen 
metatranscriptomics for the diagnosis of 
sepsis could determine whether an infection 
is present and, if an infection is present, could 
guide appropriate antimicrobial therapy.
‘Big pharma’ are pulling out of 
antimicrobial discovery and development, 
as they are faced with poor discovery 
Preventative medicine, in addition to 
education on health and the appropriate 
use of anti-infective agents, is fundamental 
in the battle against the post-antibiotic 
era. Coordinated, global surveillance and 
antibiotic-sparing efforts are needed.
Laboratories are challenged to rapidly 
respond with diagnostic testing methods 
for emerging resistance mechanisms and 
pathogens. We should view diagnostics, 
therapy and antibiotic resistance as a single 
continuous process. Results of laboratory 
testing must be integrated into diagnostic 
pathways; collaboration and integration of 
laboratory medicine professionals in patient 
care continuum is essential. Academics 
and industry must work together to build 
robust, curated repositories of pathogen 
sequence data and corresponding phenotypic 
and clinical data. These data are necessary 
to realize the potential of sequence-based 
diagnostics, computational pipelines, and the 
development of both new diagnostics and 
new anti-infective agents.
J.L. We need to continue to monitor trends 
in the epidemiology of resistant pathogens 
through global surveillance, as well as 
point prevalence studies. The availability 
of diagnostics is crucial to help generate 
meaningful data sets. The data around the 
epidemiology and spread of resistance are 
what help drug discoverers and developers 
to understand current, and predict future, 
medical need. It takes a long time to discover 
and bring a new antibacterial drug to market; 
thus, if we only react once a threat is urgent, 
we are constantly ‘fighting the last war’. The 
availability of robust diagnostics can keep us 
ahead of the threat posed by antimicrobial 
resistance and help us to place resources 
where they will have the biggest effect with 
respect to managing resistance. With such 
accurate and implementable diagnostics, and 
the necessary information technology (IT) 
systems to support these efforts, we as drug 
discoverers would have access to up-to-date 
information, on a global scale, of where the 
biggest threats and unmet medical needs lie.
P.N. Beyond the development of diagnostic 
techniques, the development of novel drugs 
is of the utmost importance to control the 
development of antimicrobial resistance. 
This development will most likely be driven 
by industry, through the development of 
novel chemical agents with antibacterial 
activity. The extensive reports of emerging 
resistance traits will pave the way for 
choosing the antibiotic to be developed. 
Moreover, antimicrobial resistance in 
prospects (very few new classes of antibiotic 
have been discovered since the 1980s) and 
diminishing returns on investment (the 
development pipeline is extremely expensive 
and antibiotics are relatively cheap drugs). 
Hence, there is a dearth of new antimicrobials 
in the pipeline. Governments must look 
beyond big pharma to, for example, small 
and medium-sized enterprises (SMEs) and 
universities, who can team up to advance 
the discovery and development of novel 
antibiotics and companion diagnostic tests. 
Clearly, the appropriate mechanisms and 
government funding need to be in place for 
this approach to be successful.
J.P. The CDC has several networks for 
evaluating and implementing novel 
diagnostics that will improve antibiotic use 
and the containment of antibiotic-resistant 
infections. Specifically, the CDC has a 
network of academic centres, the Prevention 
Epicenters, which develops and evaluates 
innovative ways, including novel diagnostics, 
to improve antibiotic stewardship and 
prevent healthcare-associated infections. 
In addition, the CDC has established the 
Antibiotic Resistance Laboratory Network 
(ARLN), which leverages public health 
laboratory capacity to fill the gaps in testing 
that is usually carried out in healthcare 
settings. The ARLN consists of seven regional 
laboratories for advanced antimicrobial 
resistance testing capacity, one national 
tuberculosis whole-genome sequencing 
laboratory, and additional testing in 57 state 
and large city laboratories. In the ARLN, the 
CDC will use innovative tools evaluated by 
other programmes to improve our ability to 
generate antimicrobial resistance data for 
containment and prevention. The CDC is also 
working to make sure that new diagnostics 
can detect all types of antibiotic resistance by 
making ARLN samples of resistant bacteria 
gathered nationwide available in the CDC 
and FDA Antibiotic Resistant Isolate Bank.
Looking beyond the development of 
diagnostics, what else is needed in the 
battle against antimicrobial resistance? For 
example, how will diagnostics inform drug 
development and the surveillance of resistance 
evolution in the laboratory? What other tools 
are needed in this pursuit?
%#&$ Even better than rapidly 
diagnosing and treating an infection would 
be preventing it from occurring in the 
first place. Vaccines are one component 
of this, as are infection prevention efforts 
in both hospital and community settings. 
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Gram-negative bacteria will continue to 
increase, as they emerge in the community 
setting (in which their spread is difficult 
or impossible to control) and resistance 
traits are being transmitted in the hospital 
settings. It is of vital importance to develop 
simple computer-based strategies for the 
identification of patients who are  
possibly infected with an antimicrobial- 
resistant pathogen at the hospital level 
to detect possible carriers of antibiotic 
resistance. For example, in many hospitals 
worldwide, it is still impossible to know 
whether the patient has been transferred 
from a hospital in which the patient could 
have been infected with a multidrug-resistant 
bacterium. In addition, the extensive 
use of precise and rapid diagnostics will 
facilitate epidemiological surveillance of 
resistance worldwide in ‘real time’. Many 
important resistance traits are still only 
being identified after the resistance trait 
has spread worldwide, as exemplified 
by the global spread of the extended-
spectrum β-lactamase CTX-M-15, and the 
carba penemases OXA-48 and more recently 
New Delhi metallo-β-lactamase.
,1o) Rapid diagnostics will enable the 
targeted recruitment of patient samples that 
contain specific pathogens with specific 
resistance profiles in clinical trials of 
antimicrobials and inhibitor combinations. 
This is currently very important; for example, 
in the development of β-lactamase inhibitor 
combinations. Currently, it is commonplace 
for more than 75% of the recruited patients 
in a trial to be infected with a pathogen that 
is sensitive to the antibiotic alone, which 
means that less than 25% of the samples can 
be used to test the inhibitor. Moreover, if 
we can replace culture-based methods with 
rapid diagnostics, clinicians can prescribe 
targeted narrow-spectrum agents. This will 
reinvigorate the antimicrobial development 
pipeline by creating a more diverse market. 
Novel narrow-spectrum agents are easier to 
discover than broad-spectrum agents (as their 
activity is for a specific pathogen or pathogen 
group rather than across a broad range of 
pathogens) and are hence potentially cheaper 
to develop, but they can only be developed 
and used if better diagnostics are in place.
The implementation of rapid and 
comprehensive diagnostics, such as 
metagenomic sequencing, will change 
public health globally. Public health 
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agencies will be able to monitor pathogens 
in real time, making it feasible to track 
outbreaks as they occur, monitor resistance 
evolution and spread, identify transmission 
events, and improve infection control 
and prevention. The depth and richness 
of the data will far outweigh current 
diagnostics data. However, there are many 
barriers to replacing culture-based methods. 
Both the personnel and infrastructure need 
to be in place to handle big data, manage 
rapid results so that they reach clinicians in 
a timely fashion and analyse and interpret 
the sequence data. Governments, regulatory 
authorities, clinicians and scientists all 
need to be willing to accept, and to drive, 
this change.
J.P. A key aspect of our efforts to combat 
antibiotic resistance is a robust IT 
infrastructure; this affects all aspects of 
antimicrobial resistance. In healthcare 
facilities, we need to ensure that diagnostic 
tests are rapidly and clearly reported to 
healthcare providers at the bedside. Too 
often, laboratory information systems and 
electronic medical records have limited 
capability to communicate complex test 
results. Public health also needs advances 
in IT. The CDC is addressing this need by 
building surveillance program to capture 
both antibiotic use and resistance data from 
electronic medical records. Healthcare 
facilities, as well as local, state and regional 
public health authorities, can use these data 
to implement containment and prevention 
measures. The CDC is also working to create 
interactive tools so that the data are easily 
accessible by the public, including academic 
and industry partners who need such data 
for strategic decision making.
Carey-Ann D. Burnham is at the Department of 
Pathology & Immunology, Washington University 
School of Medicine, 660 South Euclid Avenue, 
Campus Box 8118, St. Louis, Missouri 63110, USA. 
cburnham@wustl.edu
Jennifer Leeds is at Novartis Institutes for 
Biomedical Research, Inc., Infectious Diseases Area, 
5300 Chiron Way, Emeryville, California 94608, USA. 
jennifer.leeds@novartis.com
Patrice Nordmann is at the Medical and Molecular 
Microbiology Department of Medicine, INSERM 
European Laboratory (French National Institute for 
Health and Medical Research, Paris), 
Natural Reference Center for Emerging Antibiotic 
Resistance, University of Fribourg, Chemin du 
Musée 18, 1700 Fribourg, Switzerland. 
patrice.nordmann@unifr.ch
FURTHER INFORMATION
ResFinder: https://cge.cbs.dtu.dk/services/ResFinder/
INHALE hospital-acquired pneumonia diagnostic trial: 
http://www.ucl.ac.uk/inhale-project/overview
Prevention Epicenters:  
https://www.cdc.gov/hai/epicenters/index.html
Antibiotic Resistance Laboratory Network (ARLN):  
https://www.cdc.gov/drugresistance/solutions-initiative/
ar-lab-networks.html
CDC and FDA Antibiotic Resistant Isolate Bank: https://
www.cdc.gov/drugresistance/resistance-bank/index.html
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